Back to results
US 9,315,584 B2Granted
LH-type bispecific antibody
AssigneeTohoku University
InventorsIzumi Kumagai, Ryutaro Asano, Mitsuo Umetsu
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeTohoku University
InventorsIzumi Kumagai, Ryutaro Asano, Mitsuo Umetsu
Estimating the term…
Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (LH-diabody type bispecific antibody) characterized in that an L-chain is located in the N-terminal side in each polypeptide (LH type); a humanized high-functional bispecific antibody which contains said LH diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule.
A single-chain polypeptide which is either a first or a second polypeptide of a diabody-type bispecific antibody, said diabody-type bispecific antibody consisting of said first polypeptide comprising a humanized variable region of the light chain (5L) of an anti-human EGF receptor 1 antibody 528 and a humanized variable region of the heavy chain (OH) of an anti-CD3 antibody OKT in this order from its N-end to C-end and said second polypeptide comprising a humanized variable region of the light chain (OL) of an anti-CD3 antibody OKT and a humanized variable region of the heavy chain (5H) of an anti-human EGF receptor 1 antibody 528 in this order from its N-end to C-end.
A single-chain polypeptide which has the structure of (5LOH) or (OL5H) bonded to Fc region of a human antibody via hinge region of a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3 having the following structure:
A diabody-type bispecific antibody consisting of a first polypeptide comprising a humanized variable region of the light chain (5L) of an anti-human EGF receptor 1 antibody 528 and a humanized variable region of the heavy chain (OH) of an anti-CD3 antibody OKT in this order from its N-end to C-end;
A humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3;
Dependencies are inferred from the claim text.